BUDGET IMPACT ANALYSIS OF INTRODUCTION OF BEVACIZUMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE

被引：0
|
作者：
Ektare, V [1 ]
Liu, R. [2 ]
Stephens, J. [2 ]
Shelbaya, A. [3 ,4 ]
Yang, J. [3 ]
机构：
[1] Pharmerit India Private Ltd, Mumbai, MD, India
[2] Pharmerit Int, Bethesda, MD USA
[3] Pfizer Inc, New York, NY USA
[4] Columbia Univ, Mailman Sch Publ Hlth, New York, NY 10027 USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PBI7
引用
收藏
页码：S15 / S15
页数：1
相关论文
共 50 条
  • [1] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF RITUXIMAB BIOSIMILAR IN THE UNITED STATES FROM A PAYER PERSPECTIVE
    Ektare, V
    Liu, R.
    Stephens, J.
    Al Taie, A.
    Shelbaya, A.
    [J]. VALUE IN HEALTH, 2020, 23 : S16 - S17
  • [2] BUDGET IMPACT ANALYSIS OF INTRODUCTION OF SUBCUTANEOUS INFLIXIMAB IN FRANCE FROM A PAYER PERSPECTIVE
    Pradie, M.
    Hadjadj, C.
    Moreau, Petiteau F.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S81 - S81
  • [3] Budget impact analysis of rituximab biosimilar in Italy from the hospital and payer perspectives
    Rognoni, Carla
    Bertolani, Arianna
    Jommi, Claudio
    [J]. GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2018,
  • [4] BUDGET IMPACT ANALYSIS OF INTRODUCING FRUQUINTINIB FOR THE TREATMENT OF PREVIOUSLY TREATED METASTATIC COLORECTAL CANCER IN THE UNITED STATES FROM THE PAYER PERSPECTIVE
    Hernandez, L. G.
    Paly, V
    Li, S.
    Khanduri, P.
    Asfaw, A. A.
    Zou, D.
    [J]. VALUE IN HEALTH, 2024, 27 (06) : S106 - S106
  • [5] BUDGET IMPACT OF ZANUBRUTINIB TO TREAT RELAPSED OR REFRACTORY MARGINAL ZONE LYMPHOMA FROM A PAYER PERSPECTIVE IN THE UNITED STATES
    Liu, S.
    Yang, K.
    Carter, J.
    Zimmerman, T.
    Tang, B.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S62 - S62
  • [6] Patient-Administered Biologic and Biosimilar Filgrastim May Offer More Affordable Options for Patients with Nonmyeloid Malignancies Receiving Chemotherapy in the United States: A Budget Impact Analysis from the Payer Perspective
    Trautman, Holly
    Szabo, Erika
    James, Elizabeth
    Tang, Boxiong
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2019, 25 (01): : 94 - 101
  • [7] INTRODUCTION OF A LOW-DOSE LEVONORGESTREL INTRAUTERINE CONTRACEPTIVE SYSTEM: A THREE-YEAR BUDGET IMPACT ANALYSIS FROM A THIRD-PARTY PAYER PERSPECTIVE IN THE UNITED STATES
    Trussell, J.
    Ferrufino, C. P.
    Hawes, C.
    Pocoski, J.
    Filonenko, A.
    Kim, R. S.
    McCoy, M. A.
    Law, A. W.
    [J]. VALUE IN HEALTH, 2013, 16 (03) : A71 - A72
  • [8] Bariatric Surgery Coverage: a Comprehensive Budget Impact Analysis from a Payer Perspective
    Swetha R. Palli
    John A. Rizzo
    Natalie Heidrich
    [J]. Obesity Surgery, 2018, 28 : 1711 - 1723
  • [9] Bariatric Surgery Coverage: a Comprehensive Budget Impact Analysis from a Payer Perspective
    Palli, Swetha R.
    Rizzo, John A.
    Heidrich, Natalie
    [J]. OBESITY SURGERY, 2018, 28 (06) : 1711 - 1723
  • [10] Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives
    Jingyan Yang
    Rongzhe Liu
    Varun Ektare
    Jennifer Stephens
    Ahmed Shelbaya
    [J]. Applied Health Economics and Health Policy, 2021, 19 : 605 - 618
12345